Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06932809 · ClinicalTrials.gov registry record · Early Phase 1

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

A Early Phase 1 study of Tauopathies, sponsored by University of Pennsylvania.

Recruiting
Registry status
Early Phase 1
Development phase
90
Enrollment target
2
Study locations

NCT06932809: Recruiting Early Phase 1 study of Tauopathies, sponsored by University of Pennsylvania.

NCT06932809 is a Early Phase 1 study of Tauopathies that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 90 participants, above the 66-participant average among 5 other Tauopathies trials with a reported enrollment target (36% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06932809, a Early Phase 1 study of Tauopathies, is actively recruiting participants, sponsored by University of Pennsylvania.

RECRUITING
Registry status
Early Phase 1
Development phase
90 participants
Enrollment target
2
Study locations

Study Summary

The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathies, such as Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), syndromes of genetic Frontotemporal Lobar Degeneration (genetic FTLD) as well as participants with Parkinson disease (PD), Alzheimer's Disease (AD) and healthy controls. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WUSTL). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.

Conditions Studied

Tauopathies

Interventions

  • DIAGNOSTIC_TEST Brain MRI
  • DIAGNOSTIC_TEST Amyloid PET
  • DRUG 18F-JSS20-183A PET
  • BEHAVIORAL Neurological Assessments

Study Locations (2)

California

  • University of California - San Francisco

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2025-05-09
Est. Completion 2030-04
Phase Early Phase 1

Sponsor

University of Pennsylvania

1,423 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06932809

The ClinicalTrials.gov registry entry for NCT06932809 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 66-participant average among 5 other Tauopathies trials with a reported enrollment target (36% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tauopathies appearing as the primary indexed condition, and to 4 interventions - of which Brain MRI is the first listed.

NCT06932809 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06932809 about?

NCT06932809 is a clinical study titled "Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A". The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 18F-JSS20-183A. The goal of this radiotracer is to quantify 4Repeat Tau (4Rtau) protein that is abnormally deposited in the brain of people with a class of neurodegenerative diseases called tauopathie...

What is the current status of trial NCT06932809?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2025-05-09. Estimated completion is 2030-04.

What conditions does trial NCT06932809 study?

This clinical trial studies the following conditions: Tauopathies.

What interventions are being tested in trial NCT06932809?

The interventions under investigation include: Brain MRI (DIAGNOSTIC_TEST), Amyloid PET (DIAGNOSTIC_TEST), 18F-JSS20-183A PET (DRUG), Neurological Assessments (BEHAVIORAL).

Who is sponsoring clinical trial NCT06932809?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06932809 being conducted?

This trial has 2 study locations across California, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tauopathies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Tauopathies

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.